Our Mission

TRiCares’ mission is to revolutionize the treatment of tricuspid regurgitation (TR). We are developing Topaz, a minimally invasive tricuspid valve replacement system designed to eliminate TR and improve patient outcomes. Our goal is for Topaz to become the valve of choice for TR treatment, offering a safe and effective solution that overcomes limitations of existing approaches. 

TRiCares Team

We are a growing team, with diverse skills and experiences, who share the vision of bringing the highest-quality tricuspid regurgitation treatment to market.

Management

Ahmed
Elmouelhi

President and CEO

Ahmed
Elmouelhi

President and CEO

  • Over 20 years of experience in the medical device industry, covering strategy, sales & marketing, R&D and clinical science
  • Served as Senior Vice President of Product Marketing, Strategy and Business Development at AtriCure
  • Held major roles at Medtronic, within its Structural Heart division, and at AGA Medical (now part of Abbott Laboratories)
     

Esther
Gerteis

VP Medical & Regulatory Affairs

Esther
Gerteis

VP Medical & Regulatory Affairs

  • Over 20 years of experience in clinical research with Edwards Lifesciences, Biotronik VI and CorFlow Therapeutics
  • Specialized in interventional cardiology, surgical and transcatheter heart valve therapy, heart failure and vascular intervention across Europe, US and Asia
     

Laura
Ghione

Chief Operating Officer

Laura
Ghione

Chief Operating Officer

  • 20 years of experience in heart valves design, development and operations management 
  • Former Heart Valve R&D Senior Director at Sorin/LivaNova
  • Led the development of the first sutureless valve for the European market and US clearance
     

Lubos
Cechvala

Director of Finance

Lubos
Cechvala

Director of Finance

  • 8 years of experience in Finance and Investments in startups as well as MNCs
  • Experienced in fundraising, investor relations, controlling, accounting, contracting as well as public grants

Michael
Litzenburger

VP R&D

Michael
Litzenburger

VP R&D

  • Over 15 years structural heart experience, specific in novel technologies for Aortic, Mitral and Tricuspid valve repair and replacement
  • Member of Task force to build an R&D Team for TAVR in the USA
  • Held a key role in the R&D Team of his previous company to run successfully through FIM and CE study of a TAVR System.

Scientific Advisory Board 

  • Professor Eberhard Grube, MD, MSCAI, Professor of Medicine, Head, Center of Innovative Interventions in Cardiology (CIIC) University Hospital Bonn, Germany 
  • Professor Hendrik Treede, Director of the Department of Cardiac Surgery at the Mid-German Heart Center, University Hospital Halle (Saale).
  • Dr. Neil Fam, Director of the Structural Heart Program at St. Michael’s Hospital and the Schroeder Chair in Structural and Valve Innovation.
  • Professor Nicolas van Miegem, FESC PhD, Interventional cardiologist at Thoraxcenter, Erasmus MC, Rotterdam, NL
  • Professor Pascal Lim, Hospital Practitioner, Paris-Est Créteil University (UPEC)
  • Philipp Blanke, St Paul’s Hospital & University of British Columbia, Vancouver, British Columbia, Vancouver, Canada
  • Dr. Susheel Kodali MD, director of the Structural Heart and Valve Center at Columbia University Irving Medical Center/New York-Presbyterian Hospital.
  • Dr. Ulrich Schäfer MD, Head of Structural Heart Division at University Heart Center Hamburg-Eppendorf

Careers

Clinical Research Associate (CRA) / Clinical Project Manager (CPM) 
Full-time, Munich, Germany

R&D Engineer
Full-time, Munich, Germany

Quality and Regulatory Affairs Manager
Full-time, Munich, Germany

Please send your application and resume via email to HR@tricares.de and to the hiring manager reported in the job profile!
Please note our data protection declaration for encrypted data transmission.